Foresite returns to the SPAC well, as investors wonder how long the run can last

Jason Mast

Editor

Six months after launching his first biotech SPAC, Foresite’s Jim Tananbaum has started a second. On Tuesday, the longtime life science investor filed to raise …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Foresite returns to the SPAC well, as investors wonder how long the run can last

Jason Mast

Editor

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Bristol Myers reveals more job cuts in New Jersey

Fore­site re­turns to the SPAC well, as in­vestors won­der how long the run can last

Jason Mast

Editor

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Foresite returns to the SPAC well, as investors wonder how long the run can last

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Bristol Myers reveals more job cuts in New Jersey